repagermanium
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 17, 2021 (NCT05122182)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2INHIBITOR
CCR2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107883 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05183646 | Phase 3 | May 30, 2022 | Dimerix Bioscience Pty Ltd |
| NCT05122182 | Phase 2 | Nov 17, 2021 | University of New South Wales, University of Sydney |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dimerix Bioscience Pty Ltd | For profit | 1 | 1 | 1 | 2022 |
| University of New South Wales | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Sydney | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1